Daily digest

What's trending, October 5, 2026

In the news

Gut mRNA tech supercharges vaccine and GLP-1 delivery

News-Medical, reporting a Georgia Institute of Technology release, describes a mouse study from Georgia Tech and Emory University published in ACS Nano. Researchers used microneedle injections to deliver lipid nanoparticle mRNA to different parts of the gut, finding the site changed where particles travelled, reaching pancreas and lymph nodes while reducing liver, lung and spleen uptake. Stomach-delivered GLP-1 mRNA improved blood sugar regulation in mice.

Why it matters: Relevant to clinicians and readers following early laboratory research on GLP-1 medicines and mRNA delivery methods, noting this work so far involves only mouse models.

news-medical.net · October 5, 2026

Our summary →

In the news

Scientists just found a way to fight lung cancer and muscle wasting at the same time

ScienceDaily, relaying Oregon State University, reports a preclinical study in mice in which lipid nanoparticles carried follistatin mRNA to lung tumors. Compared with conventional nanoparticles that tend to collect in the liver, the approach achieved an approximately 2.5-fold greater reduction in tumor burden and helped preserve body weight and muscle in mice with cachexia. It has not been tested in people.

Why it matters: Relevant to Marylanders living with lung cancer or cancer-related muscle wasting, and to oncology and rehabilitation clinicians following early-stage cachexia research.

sciencedaily.com · October 5, 2026

Our summary →

AthleticsMD Clinical Desk

Today's front page

The newest articles and the day's news on GLP-1 & weight loss, Metabolic health, Hormones and more.

Go to the front page →

AthleticsMD

Schedule an evaluation

AthleticsMD in Columbia and Laurel/Fort Meade builds prehabilitation, rehabilitation and physician-guided weight-loss plans around your own history.

Schedule an evaluation →